• 1
    Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999; 583: 53840.
  • 2
    Raje N, Anderson K. Thalidomide − a revival story. N Engl J Med 1999; 341: 16069.
  • 3
    Hales B. Thalidomide on the comeback trail. Nat Med 1999; 5: 48990.
  • 4
    Schuler U, Ehninger G. Thalidomide: rationale for renewed use in immunological disorders. Drug Safety 1995; 12: 364.
  • 5
    Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumour necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173: 699703.
  • 6
    Marriott JB, Westby M, Dalgleish AG. The therapeutic potential of TNF-α inhibitors old and new. Drug Discov Today 1997; 2: 27382.
  • 7
    Moller DR, Wysocka M, Greenlee BM et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 159: 515761.
  • 8
    Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 188592.
  • 9
    Jacobson JM, Greenspan JS, Spritzler J et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997; 336: 148793.
  • 10
    Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 15869.
  • 11
    Jacobson JM, Spritzler J, Fox L et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis 1999; 180: 617.
  • 12
    Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000; 97: 10920.
  • 13
    Haslett PA, Klausner JD, Makonkawkeyoon S et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15: 116979.
  • 14
    Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002; 168: 264451.
  • 15
    Muller GW, Corral LG, Shire MG et al. Structural modifications of Thalidomide produce analogs with enhanced tumour necrosis factor inhibitory activity. J Med Chem 1996; 39: 323840.
  • 16
    Corral LG, Muller GW, Moreira AL et al. Selection of novel analogs of thalidomide with enhanced tumour necrosis factor alpha inhibitory activity. Mol Med 1996; 2: 50615.
  • 17
    Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999; 163: 3806.
  • 18
    Moreira AL, Corral LG, Ye WG et al. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Human Retroviruses 1997; 13: 85763.
  • 19
    Marriott JB, Westby M, Cookson S et al. CC-3052: a water soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. J Immunol 1998; 161: 423643.
  • 20
    Muller GW, Shire MG, Wong LM et al. Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett 1998; 8: 266974.
  • 21
    Muller GW, Chen R, Huang SY et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9: 162530.
  • 22
    Guckian M, Dransfield I, Hay P, Dalgleish AG. Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin Exp Immunol 2000; 121: 4729.
  • 23
    La Maestra L, Zaninoni A, Marriott JB et al. The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin Exp Immunol 2000; 119: 1239.
  • 24
    Hideshima T, Chauhan D, Shima Y. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 294350.
  • 25
    Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 156571.
  • 26
    Juliusson G, Celsing F, Turesson I. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 8996.
  • 27
    Zomas A, Anagnostopoulos N, Dimopoulos MA. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. Bone Marrow Transplant 2000; 25: 131920.
  • 28
    Eisen T, Boshoff C, Mak I et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 8127.
  • 29
    Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 70815.
  • 30
    Patt YZ, Hassan MM, Lozano RD et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000; 23: 31921.
  • 31
    Gutheil J, Finucane D. Thalidomide therapy in refractory solid tumour patients. Br J Haematol 2000; 110: 754.
  • 32
    Marriott JB, Muller GW, Stirling D, Dalgleish AG. Immunotherapeutic and anti-tumour potential of thalidomide analogues. Exp Opin Biol Ther 2001; 1: 67582.
  • 33
    Dredge K, Marriott JB, Todryk SM et al. Protective antitumor immunity induced by a co-stimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity J Immunol 2002; 168: 49149.
  • 34
    Tartaglia LA, Goeddel DV, Reynolds C et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumour necrosis factor receptor. J Immunol 1993; 151: 463741.
  • 35
    Lin R-H, Hwang Y-W, Yang B-C, Lin C-S. TNF receptor-2-triggered apoptosis is associated with the down regulation of Bcl-xl on activated T cells and can be prevented by CD28 co-stimulation. J Immunol 1997; 158: 598603.
  • 36
    Gori A, Rossi MC, Trabattoni D et al. Tumor necrosis factor-α increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection. J Infect Dis 2000; 182: 63940.
  • 37
    Wohl DA, Aweeka FT, Schmitz J et al. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis 2002; 185: 135963.